Hemostemix (CVE:HEM) Stock Price Up 48.3% – What’s Next?

by · The Markets Daily

Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price traded up 48.3% during mid-day trading on Thursday . The stock traded as high as C$0.24 and last traded at C$0.22. 599,100 shares were traded during trading, an increase of 40% from the average session volume of 426,900 shares. The stock had previously closed at C$0.15.

Hemostemix Price Performance

The stock has a market cap of C$20.91 million, a price-to-earnings ratio of -12.00 and a beta of 0.20. The business’s 50 day moving average is C$0.09 and its 200 day moving average is C$0.07.

About Hemostemix

(Get Free Report)

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.

Read More